NASDAQ · TRIB
Trinity Biotech plc
$6.60-$0.03 (-0.45%)
Trinity Biotech plc’s quoted price sits in the lower half of its reported 52-week range, 87.43% below the high.
Loading market information…
AMEX · SRXH · USD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 03:04 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
SRX Global Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.93% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
SRX Global Inc.’s next earnings report is currently expected on Dec 25, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow SRX Global Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
SRX Global Inc. develops artificial intelligence (AI)-powered solutions designed to improve decision-making, streamline operations, and strengthen risk management. The company is headquartered in Tampa, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:06 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $7.20M-44.19% vs estimate |
| Q4 2024 | Nov 14, 2024 | -$43.90-1,886.3% vs estimate | $11.37M-49.46% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$6.60-$0.03 (-0.45%)
Trinity Biotech plc’s quoted price sits in the lower half of its reported 52-week range, 87.43% below the high.
$13.85-$3.97 (-22.28%)
Sensei Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.32% below the high.
$1.00-$0.01 (-1.01%)
Marker Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.36% below the high.
$0.28-$0.01 (-4.32%)
AEON Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.6% below the high.
$6.21-$0.15 (-2.36%)
Bolt Biotherapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.18% below the high.
$1.20-$0.02 (-1.64%)
Cellectar Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.47% below the high.
$0.48-$0.03 (-5.24%)
Gelteq Limited Ordinary Shares’s quoted price sits in the lower half of its reported 52-week range, 76.14% below the high.
$2.34+$0.03 (+1.08%)
Beyond Air, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.61% below the high.
